Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914275 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
A Phase 3 study of Influenza, Human, sponsored by Seqirus.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,250
- Enrollment target
- 20
- Study locations
NCT02914275 is a Phase 3 study of Influenza, Human that has completed, run by Seqirus. The registered enrollment target is 2,250 participants, below the 16,099-participant average among 18 other Influenza, Human trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT02914275, a Phase 3 study of Influenza, Human, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.
Conditions Studied
Interventions
- BIOLOGICAL Seqirus Quadrivalent Inactivated Influenza Vaccine
- BIOLOGICAL Comparator Quadrivalent Inactivated Influenza Vaccine
Study Locations (20)
California
- Site 430 - Anaheim
- Site 437 - Anaheim
- Site 423 - Downey
- Site 397 - Ontario
- Site 445 - Paramount
- Site 402 - Sacramento
- Site 425 - San Diego
Kansas
- Site 390 - Augusta
- Site 421 - Newton
- Site 422 - Wichita
Kentucky
- Site 443 - Louisville
- Site 420 - Louisville
- Site 441 - Louisville
Alabama
- Site 434 - Birmingham
- Site 442 - Mobile
Florida
- Site 418 - Miami
- Site 426 - Miami
Louisiana
- Site 393 - Metairie
- Site 436 - Metairie
Idaho
- Site 289 - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,250 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2017-08-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914275
The ClinicalTrials.gov registry entry for NCT02914275 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 16,099-participant average among 18 other Influenza, Human trials with a reported enrollment target (86% lower). The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza, Human appearing as the primary indexed condition, and to 2 interventions - of which Seqirus Quadrivalent Inactivated Influenza Vaccine is the first listed.
NCT02914275 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Kansas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02914275 about?
NCT02914275 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.". This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 mo...
What is the current status of trial NCT02914275?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,250 participants. The study started on 2016-09-27. Estimated completion is 2017-08-11.
What conditions does trial NCT02914275 study?
This clinical trial studies the following conditions: Influenza, Human.
What interventions are being tested in trial NCT02914275?
The interventions under investigation include: Seqirus Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL), Comparator Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02914275?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914275 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Idaho, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
COMPLETED · Phase 3
-
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
COMPLETED · Phase 3
-
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
COMPLETED · Phase 3
-
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
RECRUITING · Phase 2
-
Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.